Prognostic stratification of acute pulmonary embolism: Focus on clinical aspects, imaging, and biomarkers

Luca Masotti¹
Marc Righini²
Nicolas Vuilleumier³
Fabio Antonelli⁴
Giancarlo Landini⁵
Roberto Cappelli⁶
Patrick Ray⁷

¹Internal Medicine, ²Clinical Chemistry, Cecina Hospital, Cecina, Italy; ³Division of Angiology and Haemostasis, Department of Internal Medicine, Geneva University Hospital, Switzerland; ⁴Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals and University of Geneva, Switzerland; ⁵Internal Medicine, Santa Maria Nuova Hospital, Florence, Italy; ⁶Thrombosis Center, University of Siena, Siena, Italy; ⁷Department of Emergency Medicine, Centre Hospitale-Universitaire Pitié-Salpêtrière, UPMC Paris 6, Paris, France

Abstract: Pulmonary embolism (PE) represents a common disease in emergency medicine and guidelines for diagnosis and treatment have had wide diffusion. However, PE morbidity and mortality remain high, especially when associated to hemodynamic instability or right ventricular dysfunction. Prognostic stratification to identify high risk patients needing to receive more aggressive pharmacological and closer monitoring is of utmost importance. Modern guidelines for management of acute PE are based on risk stratification using either clinical, radiological, or laboratory findings. This article reviews the modern treatment of acute PE, which is customized upon patient prognosis. Accordingly the current risk stratification tools described in the literature such as clinical scores, echocardiography, helical computer tomography, and biomarkers will be reviewed.

Keywords: pulmonary embolism, prognosis, troponin, BNP, NT-proBNP, echocardiography, computer tomography

Introduction

Pulmonary embolism (PE) remains one of the leading causes of morbidity and mortality in the emergency and cardiovascular setting, especially when associated to hemodynamic instability. In the United States, about 150,000 patients per year are diagnosed with acute PE, resulting in thousands of recognized deaths annually from massive PE. Mortality for PE is 2% in normotensive patients without evidence of right ventricular dysfunction (RVD), but rises up to 30% in patients with shock and up to 65% in patients with cardiac arrest at presentation.¹

Guidelines on diagnosis have had wide diffusion in the last years with strategies based on pre-test clinical probability, D-Dimers levels, ultrasonography of the legs, lung scan, and more recently computer tomography pulmonary angiography (CTPA).²⁻⁴ Concomitantly modern concepts about mortality risk evaluation, prognostic stratification and consequent treatment have also emerged. Therefore the aim of the present literature review is to summarize the concept of PE risk stratification focusing on emerging stratification tools and discuss its consequences in clinical practice.

Pathophysiology, clinical classification, and modern concepts of treatment of acute PE

The pathophysiological response to acute PE is of utmost importance to understand its hemodynamic consequences, which in turn will affect patient prognosis. Patient prognosis depends on the extent to which pulmonary artery blood flow is obstructed,
pre-existing cardiopulmonary disease, and the release of vasoactive humoral factors from clots.\textsuperscript{1,6} The mechanical obstruction formed by the clot, together with the pulmonary artery vasoconstriction stimulated by neurohumoral substances (such as serotonin from platelets, thrombin from plasma, and histamine from tissue) and hypoxemia, could cause increased pulmonary vascular resistance and right side cardiac afterload, which in turn can result in cardiac dilatation, hypokinesis, and myocardial ischemia. In some patients, a rapid progression in systemic arterial hypotension and cardiogenic shock may occur. Cardiac arrest and death could be the fatal evolution.\textsuperscript{1,6,10} This cascade could explain some important consequences in biomarkers increase; myocardial damage represented by micro-infarcts leads to increased levels of cardiac troponins (cTn) and heart type fatty acid-binding proteins (H-FABP), whereas wall stress caused by higher right heart after-load leads to increased levels of natriuretic peptides (NP). Figure 1 summarizes the hemodynamic consequences of PE.

Classically PE has been subdivided in massive, hemodynamically unstable (hypotension is defined as arterial blood pressure less than 90 mmHg, shock, or cardiac arrest), submassive (normotensive PE with evidence of RVD) or nonmassive (normotensive PE without RVD), which are both hemodynamically stable.\textsuperscript{2–5} About 5% of acute PE are represented by massive PE. About 50% of normotensive patients have trans-thoracic echocardiographic (TTE) pattern of RVD, and around 10% will die.\textsuperscript{11} The European Society of Cardiology (ESC) recommends classifying PE according to classes of risk for adverse prognosis.\textsuperscript{12} Therefore PE is divided into high risk (corresponding to massive PE with short term mortality >15%) and nonhigh risk. Nonhigh risk patients are normotensive. The presence of increased NP and/or troponins is currently not mandatory for defining the high risk class. As many normotensive patients often present with RVD and potential adverse outcomes, nonhigh risk PE has been further divided into intermediate risk (corresponding to submassive PE: normotensive plus signs of RVD and/or signs of myocardial damage, short-term mortality being 3%–15%) and in low risk (corresponding to nonmassive PE: normotensive without signs of RVD and myocardial damage, short-term mortality <3%).\textsuperscript{12} Figure 2 shows ESC criteria for risk assessment.

Acute treatment of PE is customized by mortality risk based upon prognostic stratification. In their new guidelines, the ESC and American College of Chest Physicians (ACCP) suggest treatment of PE according to clinical risk.\textsuperscript{12,13} In massive-high risk PE, thrombolysis with alteplase (rtPA), streptokinase, or urokinase is the recommended therapy. Embolectomy could represent an alternative therapy for patients with shock in the acute setting when thrombolysis is contraindicated or when it has been unsuccessful. In submassive-intermediate risk PE, thrombolysis has been proposed in selected patients at high risk for adverse outcomes.
prognosis without contraindications (grade IIB of ESC and ACCP VIII Edition), whereas intravenous unfractioned heparin (UFH) should be reserved to conditions in which thrombolysis is contraindicated (grade IA ESC and ACCP VIII Edition). In nonmassive-low risk PE, subcutaneous low-molecular weight heparins (LMWH) or fondaparinux are recommended (grade IA ESC and ACCP VIII Edition). As this subgroup of patients represent the majority of PE patients and that ambulatory treatment has been reported to be safe, early identification of such patients at admission could potentially lead to a substantial decrease in hospitalization rates and PE-related costs.

Vitamin K antagonists (VKA) should be started in the first day and should be overlapped with UFH and LMWH or fondaparinux for at least five days (grade I A ESC and ACCP VIII Edition).

Figure 3 summarizes the choice treatment in different class of risk for patients with acute PE. Thus, PE risk stratification will become fundamental not only to select appropriate treatment strategy, but also to potentially reduce the costs of PE management. For both purposes, several risk stratification algorithms have been reported in the literature, including clinical, radiological, and laboratory parameters.

**Risk evaluation and prognostic stratification**

**Clinical parameters and clinical scores**

Shock or systemic blood hypotension at presentation represent the most important clinical sign of poor prognosis in patients with acute PE. In the ICOPER Study, the mortality rate was 58.3% in patients who were hemodynamically unstable at the time of presentation and 15.1% for those who were hemodynamically stable. Other clinical variables, easily available at admission, associated to poor prognosis are represented by age over 70 years, history of bed rest over five days, cancer, chronic obstructive pulmonary disease, renal failure, heart failure, cardiovascular diseases, and tachycardia.

The Pulmonary Embolism Prognostic Index (PESI), and Geneva Prediction Rule represent two clinical scores identifying classes of patients with increased risk of adverse outcomes. These scores reliably identify low-risk patients with PE (patients classified as PESI classes I and II) who could be candidates for less costly ambulatory treatment. The major strength of these score is their easy use in all clinical setting; the disadvantage is that they have not been compared to more recent prognostic factors (such as biomarkers and imaging findings). In fact, PESI seems to be more accurate for predicting low risk patients than the Geneva Prediction Rule. The PESI score tool is displayed in Figure 4.

The shock index, heart rate (beats for minute)/systolic blood pressure (mmHg) ratio, is a simple method to predict high risk patients for adverse outcome, when its value is over 1. This ratio has been shown to be related to in-hospital mortality and it is sensitive to predict poor prognosis alone or in combination with trans-thoracic echocardiogram (TTE). 12-lead ECG findings of poor prognosis are represented by
presence and number of T waves inversion in precordial leads and QR in V1,21–23 but overall, ECG does not seem to be a reliable marker of severity of PE.

**Echocardiographic and radiological parameters**

TTE represents the most useful tool in everyday clinical practice to show RVD because of its noninvasive nature and relative low cost. Hence, RVD assessed on TTE has been described as one of the strongest predictor of early mortality in nonmassive PE.24–26

The main TTE findings detectable in PE are represented by right ventricle hypokinesis (mild, moderate, severe), right ventricle dilatation (especially represented by four chambers end-diastolic RV/left ventricular [LV] ratio \( \geq 1 \)), and signs of pulmonary hypertension. The presence of RVD is related to poor prognosis in PE with hemodynamic instability.11,25 Furthermore, TTE detects RVD in about 30%–40% of patients with PE.

**Figure 3** PE treatment according to modern guidelines.

*Abbreviations:* BNP, brain natriuretic peptide; RVD, right heart dysfunction; IV, intravenous; SC, subcutaneous.

<table>
<thead>
<tr>
<th>Predictors</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>+10</td>
</tr>
<tr>
<td>Male sex</td>
<td>+30</td>
</tr>
<tr>
<td>Cancer</td>
<td>+10</td>
</tr>
<tr>
<td>Heart failure</td>
<td>+10</td>
</tr>
<tr>
<td>COPD</td>
<td>+20</td>
</tr>
<tr>
<td>HR ( \geq 110 ) bpm</td>
<td>+10</td>
</tr>
<tr>
<td>SBP ( &lt; 100 ) mmHg</td>
<td>+30</td>
</tr>
<tr>
<td>RR ( \geq 30 )</td>
<td>+20</td>
</tr>
<tr>
<td>BT ( &lt; 36 ) °C</td>
<td>+20</td>
</tr>
<tr>
<td>Delirium</td>
<td>+60</td>
</tr>
<tr>
<td>( \text{SaO}_2 ) &lt; 90%</td>
<td>+20</td>
</tr>
</tbody>
</table>


*Abbreviations:* COPD, chronic obstructive pulmonary disease; HR, heart rate; bpm, beats per minute; SBP, systolic blood pressure; RR, respiratory rate; BT, body temperature; \( \text{SaO}_2 \), arterial saturation of oxygen.
normotensive patients (systolic blood pressure > 90 mmHg) at presentation.24,25 Thirty-day mortality of normotensive patients with RVD is two-fold compared to normotensive patients without RVD.26 RVD at presentation seems also to predict poor pulmonary clot resolution six months after the initial event and a higher incidence of VTE recurrence.28 Fremont and colleagues reported data from a monocentric study enrolling more than 1400 patients. The authors found that an TTE RV/LV diameter ratio > 0.9 was an independent risk factor for hospital mortality in normotensive patients with PE.29 A recent review has shown that in-hospital mortality of normotensive patients without RVD was 0%–9.6% compared to 11.8%–23% for patients with RVD.30 However other studies which evaluated the prognostic value of TTE in normotensive PE patients were less convincing.31,32 The limit of TTE examination is that the test is operator-dependent and not necessarily available around the clock in all institutions. Moreover TTE criteria of RVD are not definitely established.

Currently, CTPA represents the diagnostic gold standard for PE, and is widely integrated in validated diagnostic strategies.6–8,33 Recently several studies focused on the correlation between findings of CTPA, presence of RVD, and prognosis of PE.34–42 The Computer Tomography Pulmonary Embolism (CTPE) index combines distribution and severity of vascular obstruction of clots in pulmonary circulation; PE severity seems to be linearly related to CTPE index values.40 Ghanima and colleagues have proposed to divide the pulmonary vascular tree in four groups of arteries: sub-segmental, segmental, lobar, and main pulmonary artery with its (left and right) branches (respectively named 1, 2, 3, 4).41 These authors showed that the pulmonary artery obstruction index was correlated to troponin T levels, CTPA RV/LV diameter ratio and partial pressure of oxygen in arterial blood (PaO₂).41 It seems that the Ghanima index could be related also to TTE RVD.43 A RV/LV diameter ratio is also easily determined by CTPA and the thirty-day mortality rate is 15.6% in patients with CTPA RV/LV > 0.9 compared to 7.7% in patients without RV enlargement.44 However these results have not been confirmed in the PIOPED II trial.44 Finally, CTPA seems to be a promising method for PE prognosis stratification, but the sample size of these previous studies precludes any firm conclusion. Thus, further studies are warranted to assess CTPA as a prognostic tool, because it could be very useful for clinicians to have at the same time a validated diagnostic tool, with an additional prognostic value.

Pulmonary real-time magnetic resonance (rtMR) and magnetic resonance angiography (MRA) represent a safe alternative and/or complementary examination compared with CTPA both as diagnostic imaging and for detecting RV enlargement or dysfunction.45–49

**Laboratory parameters**

Arterial blood gas analysis (BGA) remains a first-line examination in patients with suspected PE for evaluation of gas exchange and acid-base status. The role of BGA as prognosticator has been studied with discordant results between younger and elderly patients. Much recently hypoxemia was found as an independent negative predictor of three-month all-cause mortality in PE patients (hazard ratio [HR] 5.7, 95% confidence interval [CI]: 2.1–15.1).46 PaO₂ values have been demonstrated to be linearly associated to CTPA parameters such as proximal extension of pulmonary clots and RV/LV diameter.47 Parameters derived from BGA, such as alveolar-arterial oxygen gradient (values > 50 mmHg) and arterial–alveolar oxygen tension ratio (values < 0.50) have been demonstrated to be associated to poor prognosis in nonelderly patients with PE.51,52 Moreover, alveolar dead space measured from volumetric capnography and BGA seems to correlate with embolic burden of PE.48 In elderly PE patients, only lower arterial oxygen saturation seems to predict short-term mortality; neither PaO₂ nor alveolar–arterial oxygen gradient seem to identify high risk patients.49

D-Dimer values seems to be linearly related to the extend of the clot and the severity of PE.43,53–57 One study demonstrated that patients who had D-Dimer levels below 1500 µg/L have a very low mortality.56

As detailed below, cardiac biomarkers, such as cardiac troponins, (cTnI and cTnT), NP, H-FABP, myoglobin, and growth differentiation factor-15 have been extensively evaluated as risk stratification tools in PE.

Troponins are released in the bloodstream in presence of myocardial damage secondary to microinfarction.58 The increase of troponins is correlated with TTE RVD and CTPA findings and its elevation has a strong negative prognostic value.59 Many studies have demonstrated the negative prognostic values of increased troponins in PE.60–64 Becattini and colleagues have published a meta-analysis on the relation between troponins and mortality and morbidity in acute PE.65 They confirmed that the increase of troponins I and/or T was associated with a higher mortality (17.9% in patients with elevated troponin levels and 2.3% in patients with normal troponin levels), even in the subgroup of hemodynamically stable patients (odds ratio, 4.12).65,66 Jimenez and colleagues also confirmed in a large prospective study that elevated cTnl predicted fatal PE in hemodynamically stable patients; the negative predictive value of a negative cTnl for mortality was 93%.67
NP secretion is due to RV wall stretch and therefore due to RVD. The increase of the B (B type) NP biomarker (BNP and its amino terminal portion, NT-proBNP) is highly sensitive but poorly specific for detecting RVD and patients at risk of severe adverse events such as cardiac arrest, shock, need for thrombolysis or vasopressors or mechanical ventilation, or need for intensive care units. Two studies suggested that NT-proBNP correlated better with prognosis when compared to troponins, especially in combination with TTE. Several recent reviews and meta-analyses strongly confirmed the prognostic usefulness of NP.

H-FABP, a small cytosolic protein released earlier than troponins into circulation when the myocardium is injured, has been evaluated as a prognostic tool and small studies suggested that this cardiac biomarker could also identify the patients with poorer outcomes when compared to cTns and BNP/NT-proBNP. The negative prognostic role of myoglobin and growth-differentiation factor-15 (gdf-15), a cytokine induced in the heart after ischemia or pressure overload, in acute PE have also been reported. However, H-FABP and gdf-15 measurements are not yet widely available.

Figure 5 summarizes the results of studies which evaluated various clinical, instrumental, and laboratory indexes for predicting poor outcomes in acute PE. This figure suggests that cardiac biomarkers have all been shown to correlate with RV dysfunction/dilatation and prognosis in PE.

However, because most of those studies did not perform an extensive comparison between all the available biomarkers, knowing which one will yield the best prognostic value still remains debated. Among other limitations worth to be mentioned are that different biomarkers thresholds were used (and often determined retrospectively), and that various outcome definitions were used in the aforementioned studies. In order to compare their respective prognostic value, it will be necessary to use uniform pre-defined cut-offs. One possibility would be to use the cut-offs validated in their respective initial context. To this respect, a small systematic prospective comparative study using the pre-defined and validated thresholds (either in acute coronary syndrome or heart failure) for NT-proBNP, BNP, H-FABP, and myoglobin showed that only NPs (BNP or NT-proBNP) were significantly correlated with RV dilatation on CTPA. Those results are corroborated by a recent multicentre study showing that NT-proBNP appeared as the most effective biomarker for rule-out purposes in non-massive PE. Using the commonly defined cut-off of 300 pg/ml validated for heart failure, this test had a negative predictive value of 100% (95% CI: 91–100).

Defining which of those biomarkers should be used as rule-out or rule-in test needs further clarification, but based

<table>
<thead>
<tr>
<th>Clinical parameters</th>
<th>Instrumental parameters</th>
<th>Laboratory parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>– Shock/Hypotension</td>
<td>– 12-lead ECG</td>
<td>– Increasingtroponins I or T, BNP or NT-proBNP, H-FABP, myoglobin, GDF-15</td>
</tr>
<tr>
<td>SBP ≤ 90 mmHg</td>
<td>Presence and number of T waves</td>
<td></td>
</tr>
<tr>
<td>&gt; 1</td>
<td>Inversion in precordial leads</td>
<td></td>
</tr>
<tr>
<td>Class III, IV, V</td>
<td>RVD findings</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CPTE index, proximal clot</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RV/RV diameter ratio &gt; 1</td>
<td></td>
</tr>
</tbody>
</table>

Figure 5 Clinical, instrumental and laboratory parameters associated with adverse outcomes in patients with acute PE.

Abbreviations: SBP, systolic blood pressure; ECG, electrocardiogram; ESI, Pulmonary Embolism Severity Index; RVD, right ventricular dysfunction; CTPA, computer tomography pulmonary angiography; BNP, brain natriuretic peptides; H-FABP, heart type fatty acid binding protein; GDF-15, Growth differentiation factor-15; CPTE, computer tomography pulmonary embolism.
upon the aforementioned observations, it appears that BNP/NT-proBNP and cTnI could potentially be used as rule-out tests. Finally, determining whether a biomarker alone or in combination with other clinical or radiological or ECG features would add incremental prognostic value deserves further study. Overall, NP (BNP or NT-proBNP) and cTns, with their 24-hour availability in most of emergency laboratories, could represent very convenient prognostic tools for PE risk stratification in an acute setting, especially in the institutions where echocardiography is not widely available.

Concerning the identification of patients, two major points are under investigation. First, it becomes of utmost importance to select patients who may be safely treated on an outpatient basis, and both clinical scores or probably biomarkers like NT-pro-BNP may fulfill this request. This hypothesis is being currently tested in a prospective study (the OTPE trial). Second, there is a need to better define which patient may benefit from fibrinolysis, and at least one randomized study is comparing anticoagulation against fibrinolysis in patients with no hemodynamic failure and RVD on TTE. These currently ongoing studies should allow improvements in the care of PE patients in the near future.

Conclusions
Risk evaluation and prognostic stratification are the cornerstones of modern acute PE management. The use of either clinical, ECG, or biochemical parameters will probably be crucial to appropriately select stable patients for fibrinolysis, which currently represents one of the utmost therapeutic challenges of PE. For the time being, the remaining questions are: 1) which treatment should be reserved to submassive PE patients? 2) What is the best modality to identify such patients: TTE, CTPA, biomarkers, or clinical scores? 3) Could a combination of such stratification tools add incremental value to one modality alone?

Intend-to-treat and noninferiority trials are now requested to resolve those matters. In this respect, the results of ongoing randomized multicenter trials, such as the European Pulmonary Embolism Thrombolysis (PEITHO) trial, are eagerly awaited.

Disclosure
The authors report no conflicts of interest in this work.

References


27. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mmHg or higher. *Arch Intern Med*. 2005;165:1777–1781.


